nach oben

Erschienen in:

01.10.2023 | Original Communication

Neuroimaging determinants of cognitive impairment in the memory clinic: how important is the vascular burden?

verfasst von: Daniela Andriuta, Emmanuel Wiener, Alexandre Perron, Elisa Ouin, Ines Masmoudi, William Thibaut, Jeanne Martin, Martine Roussel, Jean-Marc Constans, Ardalan Aarabi, Olivier Godefroy

Erschienen in: Journal of Neurology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

While neurodegenerative and vascular neurocognitive disorder (NCD) often co-occur, the contribution of vascular lesions, especially stroke lesions identified on MRI, to global cognition in a real-life memory clinic population remains unclear. The main objective of this retrospective study was to determine NCD neuroimaging correlates: the GM atrophy pattern and vascular lesions (especially stroke lesion localization by voxel-based lesion-symptom mapping, VLSM) in a memory clinic. We included 336 patients with mild or major NCD who underwent cerebral MRI and a neuropsychological assessment. The GM atrophy pattern (obtained by voxel-based morphometry, VBM) and the stroke lesion localization (obtained by VLSM) associated with G5 z-score (a global cognitive score), were included as independent variables with other neuroimaging and clinical indices in a stepwise linear regression model. The mean age was 70.3 years and the mean MMSE score 21.3. On MRI, 75 patients had at least one stroke lesion. The G 5 z-score was associated with GM density in the pattern selected by the VBM analysis (R² variation = 0.166, p < 0.001) and the presence of a stroke lesion in the region selected by the VSLM analysis (mainly in the right frontal region; R² variation = 0.018, p = 0.008). The interaction between the two factors was insignificant (p = 0.374). In conclusion, in this first study combining VBM and VLSM analysis in a memory clinic, global cognition was associated with a specific GM atrophy pattern and the presence of a stroke lesion mainly in the right frontal region.

Neuropathology Group. Medical Research Council Cognitive Function and Aging Study (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357:169–175. https://doi.org/10.1016/s0140-6736(00)03589-3CrossRef

van der Flier WM, Scheltens P (2005) Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 76:v2–v7. https://doi.org/10.1136/jnnp.2005.082867CrossRefPubMedPubMedCentral

Picard C, Pasquier F, Martinaud O et al (2011) Early onset dementia: characteristics in a large cohort from academic memory clinics. Alzheimer Dis Assoc Disord 25:203–205. https://doi.org/10.1097/WAD.0b013e3182056be7CrossRefPubMed

Duyckaerts C, Bennecib M, Grignon Y et al (1997) Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol Aging 18:267–273CrossRefPubMed

Seab JP, Jagust WJ, Wong ST et al (1988) Quantitative NMR measurements of hippocampal atrophy in Alzheimer’s disease. Magn Reson Med 8:200–208CrossRefPubMed

Dickerson BC, Bakkour A, Salat DH et al (2009) The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 19:497–510. https://doi.org/10.1093/cercor/bhn113CrossRefPubMed

Besson FL, La Joie R, Doeuvre L et al (2015) Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer’s disease. J Neurosci 35:10402–10411. https://doi.org/10.1523/JNEUROSCI.0150-15.2015CrossRefPubMedPubMedCentral

Alexander SK, Rittman T, Xuereb JH et al (2014) Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatr 85:925–929. https://doi.org/10.1136/jnnp-2013-307035CrossRef

Boxer AL, Yu J-T, Golbe LI et al (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. The Lancet Neurology 16:552–563. https://doi.org/10.1016/S1474-4422(17)30157-6CrossRefPubMedPubMedCentral

10.

Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006–1014. https://doi.org/10.1212/WNL.0b013e31821103e6CrossRefPubMedPubMedCentral

11.

McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89:88–100. https://doi.org/10.1212/WNL.0000000000004058CrossRefPubMedPubMedCentral

12.

Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477. https://doi.org/10.1093/brain/awr179CrossRefPubMedPubMedCentral

13.

Yang J, Pan P, Song W et al (2012) Voxelwise meta-analysis of gray matter anomalies in Alzheimer’s disease and mild cognitive impairment using anatomic likelihood estimation. J Neurol Sci 316:21–29. https://doi.org/10.1016/j.jns.2012.02.010CrossRefPubMed

14.

Meeter LH, Kaat LD, Rohrer JD, van Swieten JC (2017) Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol 13:406–419. https://doi.org/10.1038/nrneurol.2017.75CrossRefPubMed

15.

Ossenkoppele R, Pijnenburg YAL, Perry DC et al (2015) The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain 138:2732–2749. https://doi.org/10.1093/brain/awv191CrossRefPubMedPubMedCentral

16.

Harper L, Bouwman F, Burton EJ et al (2017) Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. J Neurol Neurosurg Psychiatry 88:908–916. https://doi.org/10.1136/jnnp-2016-314978CrossRefPubMed

17.

Sachdev P, Kalaria R, O’Brien J et al (2014) Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord 28:206–218. https://doi.org/10.1097/WAD.0000000000000034CrossRefPubMedPubMedCentral

18.

Puy L, Barbay M, Roussel M et al (2018) Neuroimaging determinants of poststroke cognitive performance: the GRECogVASC study. Stroke 49:2666–2673. https://doi.org/10.1161/STROKEAHA.118.021981CrossRefPubMed

19.

Weaver NA, Zhao L, Biesbroek JM et al (2019) The Meta VCI Map consortium for meta-analyses on strategic lesion locations for vascular cognitive impairment using lesion-symptom mapping: Design and multicenter pilot study. Alzheimer’s Dementia Diagnosis Assessment Disease Monit 11:310–326. https://doi.org/10.1016/j.dadm.2019.02.007CrossRef

20.

Weaver NA, Kuijf HJ, Aben HP et al (2021) Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts. Lancet Neurol 20:448–459. https://doi.org/10.1016/S1474-4422(21)00060-0CrossRefPubMed

21.

White L, Small BJ, Petrovitch H et al (2005) Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia aging study. J Geriatr Psychiatry Neurol 18:224–227. https://doi.org/10.1177/0891988705281872CrossRefPubMed

22.

Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66:200–208. https://doi.org/10.1002/ana.21706CrossRefPubMedPubMedCentral

23.

Kapasi A, DeCarli C, Schneider JA (2017) Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol 134:171–186. https://doi.org/10.1007/s00401-017-1717-7CrossRefPubMedPubMedCentral

24.

Oveisgharan S, Dawe RJ, Yu L et al (2022) Frequency and underlying pathology of pure vascular cognitive impairment. JAMA Neurol 79:1277. https://doi.org/10.1001/jamaneurol.2022.3472CrossRefPubMedPubMedCentral

25.

Toledo JB, Arnold SE, Raible K et al (2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain 136:2697–2706. https://doi.org/10.1093/brain/awt188CrossRefPubMedPubMedCentral

26.

Gladman JT, Corriveau RA, Debette S et al (2019) Vascular contributions to cognitive impairment and dementia: research consortia that focus on etiology and treatable targets to lessen the burden of dementia worldwide. Alzheimer’s Dementia Transl Res Clin Interv 5:789–796. https://doi.org/10.1016/j.trci.2019.09.017CrossRef

27.

Gorelick PB, Scuteri A, Black SE et al (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:2672–2713. https://doi.org/10.1161/STR.0b013e3182299496CrossRefPubMedPubMedCentral

28.

Sweeney MD, Montagne A, Sagare AP et al (2019) Vascular dysfunction—the disregarded partner of Alzheimer’s disease. Alzheimers Dement 15:158–167. https://doi.org/10.1016/j.jalz.2018.07.222CrossRefPubMedPubMedCentral

29.

Heinen R, Groeneveld ON, Barkhof F et al (2020) Small vessel disease lesion type and brain atrophy: the role of co-occurring amyloid. Alzheimers Dement (Amst) 12:e12060. https://doi.org/10.1002/dad2.12060CrossRefPubMed

30.

Boomsma JMF, Exalto LG, Barkhof F et al (2017) Vascular cognitive impairment in a memory clinic population: rationale and design of the “Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment” (TRACE-VCI) study. JMIR Res Protoc 6:e60. https://doi.org/10.2196/resprot.6864CrossRefPubMedPubMedCentral

31.

Association American Psychiatric (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5th Revised. American Psychiatric Publishing, WashingtonCrossRef

32.

Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279. https://doi.org/10.1016/j.jalz.2011.03.008CrossRefPubMedPubMedCentral

33.

McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005CrossRefPubMedPubMedCentral

34.

Nelson PT, Dickson DW, Trojanowski JQ et al (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142:1503–1527. https://doi.org/10.1093/brain/awz099CrossRefPubMedPubMedCentral

35.

Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853–864. https://doi.org/10.1002/mds.26987CrossRefPubMedPubMedCentral

36.

Oslin D, Atkinson RM, Smith DM, Hendrie H (1998) Alcohol related dementia: proposed clinical criteria. Int J Geriatr Psychiatry 13:203–212CrossRefPubMed

37.

Nakajima M, Yamada S, Miyajima M et al (2021) Guidelines for management of idiopathic normal pressure hydrocephalus (third edition): endorsed by the Japanese Society of normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 61:63–97. https://doi.org/10.2176/nmc.st.2020-0292CrossRefPubMed

38.

Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13:614–629. https://doi.org/10.1016/S1474-4422(14)70090-0CrossRefPubMed

39.

Godefroy O, Leclercq C, Roussel M et al (2012) French adaptation of the vascular cognitive impairment harmonization standards: the GRECOG-VASC study. Int J Stroke 7:362–363. https://doi.org/10.1111/j.1747-4949.2012.00794.xCrossRefPubMed

40.

Kalafat M, Hugonot-Diener L, Poitrenaud J (2003) Standardisation et étalonnage français du Mini Mental State (MMS) version GRÉCO. Rev Neuropsychol 13:209–236

41.

Thuillard Colombo F, Assal G (1992) Adaptation française du test de dénomination de Boston. Versions abrégées. Eur Rev Appl Psychol 42:67–73

42.

Deloche G, Hannequin D (1997) Test de dénomination orale d’images: DO 80. Éd. du Centre de psychologie appliquée, Paris, France

43.

Albert ML (1973) A simple test of visual neglect. Neurology 23:658–664CrossRefPubMed

44.

Rey A (1959) Test de copie d’une figure complexe: Manuel., Les éditions du Centre de Psychologie Appliquée. Paris

45.

Van der Linden M, Coyette F, Poitrenaud J, et les membres du GREMEM (2004) L’épreuve de rappel libre/rappel indicé à 16 items (RL/RI-16)"L’évaluation des troubles de la mémoire. Présentation de quatre tests de mémoire épisodique". Solal, Marseille

46.

Baddeley A, Emslie H, Nimmo-Smith I (1994) Doors and people: a test of visual and verbal recall and recognition. Thames Valley Test Company, Suffolk

47.

Wechsler D, Grégoire J (2000) Echelle d’Intelligence de Wechsler pour adultes: manuel : WAIS-III. Les Editions du Centre de Psychologie Appliquée, Paris

48.

Godefroy O, Azouvi P, Robert P et al (2010) Dysexecutive syndrome: diagnostic criteria and validation study. Ann Neurol 68:855–864. https://doi.org/10.1002/ana.22117CrossRefPubMed

49.

Cardebat D, Doyon B, Puel M et al (1990) Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 90:207–217PubMed

50.

Reitan R (1958) Validity of trail making tests as an indicator of organic brain damage, Percept Mot skill

51.

Godefroy O, Grefex (Groupe de Réflexion pour l’évaluation des Fonctions EXécutives) (2008) Fonctions exécutives et pathologies neurologiques et psychiatriques: évaluation en pratique clinique, Solal. Marseille

52.

Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389CrossRefPubMed

53.

Lewinsohn PM, Seeley JR, Roberts RE, Allen NB (1997) Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging 12:277–287CrossRefPubMed

54.

Goldberg D, Bridges K, Duncan-Jones P, Grayson D (1988) Detecting anxiety and depression in general medical settings. BMJ 297:897–899CrossRefPubMedPubMedCentral

55.

Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186CrossRefPubMed

56.

Godefroy O, Gibbons L, Diouf M et al (2014) Validation of an integrated method for determining cognitive ability: Implications for routine assessments and clinical trials. Cortex 54:51–62. https://doi.org/10.1016/j.cortex.2014.01.016CrossRefPubMedPubMedCentral

57.

Roussel M, Godefroy O (2016) La batterie GRECOGVASC : Evaluation et diagnostic des troubles neurocognitifs vasculaires avec ou sans contexte d’accident vasculaire cérébral. DE BOECK UNIVERSITE

58.

Box GEP, Cox DR (1964) An analysis of transformations. Journal of the Royal Statistical Society Series B (Methodological 211–252

59.

Dufouil C, Dubois B, Vellas B, et al (2017) Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimer’s Res Ther. https://doi.org/10.1186/s13195-017-0288-0

60.

Godefroy O, Duhamel A, Leclerc X, et al (1998) Brain–behaviour relationships. Some models and related statistical procedures for the study of brain-damaged patients. Brain 121(Pt 8):1545–1556

61.

Hachinski V, Iadecola C, Petersen RC et al (2006) National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 37:2220–2241. https://doi.org/10.1161/01.STR.0000237236.88823.47CrossRefPubMed

62.

Cordonnier C, Potter GM, Jackson CA et al (2009) improving interrater agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS). Stroke 40:94–99. https://doi.org/10.1161/STROKEAHA.108.526996CrossRefPubMed

63.

Wardlaw JM, Smith EE, Biessels GJ et al (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12:822–838. https://doi.org/10.1016/S1474-4422(13)70124-8CrossRefPubMedPubMedCentral

64.

Fazekas F, Chawluk JB, Alavi A et al (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 149:351–356. https://doi.org/10.2214/ajr.149.2.351CrossRefPubMed

65.

Wahlund LO, Barkhof F, Fazekas F et al (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32:1318–1322. https://doi.org/10.1161/01.str.32.6.1318CrossRefPubMed

66.

Scheltens P, Leys D, Barkhof F et al (1992) Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatr 55:967–972CrossRef

67.

Charidimou A, Linn J, Vernooij MW et al (2015) Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. Brain 138:2126–2139. https://doi.org/10.1093/brain/awv162CrossRefPubMed

68.

Doubal FN, MacLullich AMJ, Ferguson KJ et al (2010) Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 41:450–454. https://doi.org/10.1161/STROKEAHA.109.564914CrossRefPubMed

69.

Schmidt P, Gaser C, Arsic M et al (2012) An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage 59:3774–3783. https://doi.org/10.1016/j.neuroimage.2011.11.032CrossRefPubMed

70.

Ashburner J, Friston KJ (2005) Unified segmentation. Neuroimage 26:839–851. https://doi.org/10.1016/j.neuroimage.2005.02.018CrossRefPubMed

71.

Resnick SM, Pham DL, Kraut MA et al (2003) Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci 23:3295–3301CrossRefPubMedPubMedCentral

72.

Tzourio-Mazoyer N, Landeau B, Papathanassiou D et al (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273–289. https://doi.org/10.1006/nimg.2001.0978CrossRefPubMed

73.

Arnoux A, Toba MN, Duering M et al (2018) Is VLSM a valid tool for determining the functional anatomy of the brain? Usefulness of additional Bayesian network analysis. Neuropsychologia 121:69–78. https://doi.org/10.1016/j.neuropsychologia.2018.10.003CrossRefPubMed

74.

Arnoux A, Triquenot-Bagan A, Andriuta D et al (2017) Imaging characteristics of venous parenchymal abnormalities. Stroke 48:3258–3265. https://doi.org/10.1161/STROKEAHA.117.017937CrossRefPubMed

75.

Catani M, Thiebaut de Schotten M (2008) A diffusion tensor imaging tractography atlas for virtual in vivo dissections. Cortex 44:1105–1132. https://doi.org/10.1016/j.cortex.2008.05.004CrossRefPubMed

76.

Vermeer SE, Prins ND, den Heijer T et al (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348:1215–1222. https://doi.org/10.1056/NEJMoa022066CrossRefPubMed

77.

Olsson Y, Brun A, Englund E (1996) Fundamental pathological lesions in vascular dementia. Acta Neurol Scand 94:31–38. https://doi.org/10.1111/j.1600-0404.1996.tb00370.xCrossRef

78.

Knopman DS, Parisi JE, Boeve BF et al (2003) Vascular dementia in a population-based autopsy study. Arch Neurol 60:569–575. https://doi.org/10.1001/archneur.60.4.569CrossRefPubMed

79.

Ferrer I (2010) Cognitive impairment of vascular origin: neuropathology of cognitive impairment of vascular origin. J Neurol Sci 299:139–149. https://doi.org/10.1016/j.jns.2010.08.039CrossRefPubMed

80.

Ishii K, Kawaguchi T, Shimada K et al (2008) Voxel-based analysis of gray matter and CSF space in idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Disord 25:329–335. https://doi.org/10.1159/000119521CrossRefPubMed

81.

Syaifullah AH, Shiino A, Fujiyoshi A et al (2021) Alcohol drinking and brain morphometry in apparently healthy community-dwelling Japanese men. Alcohol 90:57–65. https://doi.org/10.1016/j.alcohol.2020.11.006CrossRefPubMed

82.

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMed

83.

Braak H, Braak E (1995) Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 16:271–278; discussion 278–284

84.

Ozzoude M, Ramirez J, Raamana PR et al (2020) Cortical Thickness estimation in individuals with cerebral small vessel disease, focal atrophy, and chronic stroke lesions. Front Neurosci 14:598868. https://doi.org/10.3389/fnins.2020.598868CrossRefPubMedPubMedCentral

85.

Debette S, Markus HS (2010) The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 341:c3666. https://doi.org/10.1136/bmj.c3666CrossRefPubMedPubMedCentral

86.

Jacobs HIL, Visser PJ, Van Boxtel MPJ et al (2012) Association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiol Aging 33:201.e1–8. https://doi.org/10.1016/j.neurobiolaging.2010.07.015CrossRefPubMed

87.

Choe YM, Baek H, Choi HJ et al (2022) Association between enlarged perivascular spaces and cognition in a memory clinic population. Neurology. https://doi.org/10.1212/WNL.0000000000200910.10.1212/WNL.0000000000200910CrossRefPubMedPubMedCentral

88.

Godefroy O, Spagnolo S, Roussel M, Boucart M (2010) Stroke and action slowing: mechanisms, determinants and prognosis value. Cerebrovasc Dis 29:508–514. https://doi.org/10.1159/000297968CrossRefPubMed

89.

Roussel M, Martinaud O, Hénon H, et al (2016) The behavioral and cognitive executive disorders of stroke: the GREFEX Study. PLoS One. https://doi.org/10.1371/journal.pone.0147602

Titel: Neuroimaging determinants of cognitive impairment in the memory clinic: how important is the vascular burden?
verfasst von: Daniela Andriuta
Emmanuel Wiener
Alexandre Perron
Elisa Ouin
Ines Masmoudi
William Thibaut
Jeanne Martin
Martine Roussel
Jean-Marc Constans
Ardalan Aarabi
Olivier Godefroy
Publikationsdatum: 01.10.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 1/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12009-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Update on leukodystrophies and developing trials

Correction to: Predicting neurologic recovery after severe acute brain injury using resting-state networks

Clinical and genetic analyses of a Swedish patient series diagnosed with ataxia

Insomnia and sleep-disordered breathing in FKRP-related limb-girdle muscular dystrophy R9. The Norwegian LGMDR9 cohort study (2020)

Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case–control study in an English population-based cohort